Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency

Nature Communications

Volumn 4, Issue , 2013, Pages

  Guo, Shui Long ^a,b   Ye, Hui ^c   Teng, Yan ^a   Wang, You Liang ^a   Yang, Guan ^a   Li, Xiu Bin ^a   Zhang, Chong ^c   Yang, Xue ^c   Yang, Zhong Zhou ^d   Yang, Xiao ^a,c  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CDC25A PROTEIN; CYCLIN D1; MICRORNA; MICRORNA 365; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG;

BIOCHEMISTRY; CANCER; CARCINOGEN; GENE EXPRESSION; HISTOLOGY; RODENT; TUMOR;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE INACTIVATION; HUMAN; HUMAN TISSUE; HYPERPLASIA; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; STOMACH CANCER; STOMACH CARCINOGENESIS; TRANSCRIPTION REGULATION; TUMOR DIFFERENTIATION; TUMOR INVASION; UPREGULATION;

MUS;

AGED; ANIMALS; CDC25 PHOSPHATASES; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICRORNAS; MIDDLE AGED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84889247487     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3544     Document Type: Article

References (54)

1. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA. Cancer J. Clin. 55, 74-108 (2005). (Pubitemid 40372904)
2. Milne, A. N., Carneiro, F., O'Morain, C. & Offerhaus, G. J. Nature meets nurture: molecular genetics of gastric cancer. Hum. Genet. 126, 615-628 (2009).
3. Hartgrink, H. H., Jansen, E. P., van Grieken, N. C. & van de Velde, C. J. Gastric cancer. Lancet 374, 477-490 (2009).
4. Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283-296 (2012).
5. Byun, D. S. et al. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int. J. Cancer 104, 318-327 (2003).
6. Oki, E. et al. Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. J. Gastroenterol. Hepatol. 21, 814-818 (2006). (Pubitemid 43793276)
7. Hino, R. et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 69, 2766-2774 (2009).
8. Lee, H. S., Lee, H. K., Kim, H. S., Yang, H. K. & Kim, W. H. Tumour suppressor gene expression correlates with gastric cancer prognosis. J. Pathol. 200, 39-46 (2003). (Pubitemid 36592634)
9. Zheng, H. et al. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J. Clin. Pathol. 60, 273-277 (2007). (Pubitemid 46447742)
10. Ang, K. L., Shi, D. L., Keong, W. W. & Epstein, R. J. Upregulated Akt signaling adjacent to gastric cancers: implications for screening and chemoprevention. Cancer Lett. 225, 53-59 (2005). (Pubitemid 40732768)
11. Cinti, C. et al. Activated Akt as an indicator of prognosis in gastric cancer. Virchows. Arch. 453, 449-455 (2008).
12. Kobayashi, I., Semba, S., Matsuda, Y., Kuroda, Y. & Yokozaki, H. Significance of Akt phosphorylation on tumour growth and vascular endothelial growth factor expression in human gastric carcinoma. Pathobiology 73, 8-17 (2006). (Pubitemid 43952601)
13. Kang, M. H., Kim, J. S., Seo, J. E., Oh, S. C. & Yoo, Y. A. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp. Cell Res. 316, 24-37 (2010).
14. Kang, M. J. et al. NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology 135, 2030-2042 (2008).
15. Lin, H. L. et al. 2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer. Int. J. Cancer 121, 2547-2555 (2007).
16. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
17. Ebert, M. S. & Sharp, P. A. Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515-524 (2012).
18. Lujambio, A. & Lowe, S. W. The microcosmos of cancer. Nature 482, 347-355 (2012).
19. Ueda, T. et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 11, 136-146 (2010).
20. Carvalho, J. et al. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J. Pathol. 228, 31-44 (2012).
21. Tsukamoto, Y. et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 70, 2339-2349 (2010).
22. Song, J. H. & Meltzer, S. J. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 143, 35-47 e32 (2012).
23. Wu, W. K. et al. MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 29, 5761-5771 (2010).
24. Cha, S. T. et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumour angiogenesis. Cancer Res. 70, 2675-2685 (2010).
25. Iliopoulos, D. et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci. Signal. 2, ra62 (2009).
26. Sachdeva, M., Liu, Q., Cao, J., Lu, Z. & Mo, Y. Y. Negative regulation of miR-145 by C/EBP-beta through the Akt pathway in cancer cells. Nucleic Acids Res. 40, 6683-6692 (2012).
27. Sachdeva, M. et al. p53 represses c-Myc through induction of the tumour suppressor miR-145. Proc. Natl Acad. Sci. USA 106, 3207-3212 (2009).
28. Backman, S. A. et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat. Genet. 29, 396-403 (2001). (Pubitemid 34326689)
29. Meng, F. et al. Surfactant protein A promoter directs the expression of Cre recombinase in brain microvascular endothelial cells of transgenic mice. Matrix Biol. 26, 54-57 (2007). (Pubitemid 46072712)
30. Ishimoto, T. et al. CD44 slow-cycling tumour cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci. 101, 673-678 (2010).
31. Barker, N. et al. Lgr5(ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6, 25-36 (2010).
32. Nie, J. et al. microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis 33, 220-225 (2011).
33. Sun, L. et al. Mir193b-365 is essential for brown fat differentiation. Nat. Cell Biol. 13, 958-965 (2011).
34. Xu, Z. et al. miR-365, a novel negative regulator of interleukin-6 gene expression, is cooperatively regulated by Sp1 and NF-kappaB. J. Biol. Chem. 286, 21401-21412 (2011).
35. Zhou, B. P. et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3, 973-982 (2001). (Pubitemid 34428742)
36. Ogawara, Y. et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 277, 21843-21850 (2002). (Pubitemid 34952337)
37. Di, R. et al. S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt. Biochem. J. 441, 199-207 (2012).
38. Chen, M. L. et al. The deficiency of Akt1 is sufficient to suppress tumour development in Pten/- mice. Genes Dev. 20, 1569-1574 (2006).
39. Stiles, B. et al. Essential role of AKT-1/protein kinase B alpha in PTENcontrolled tumorigenesis. Mol. Cell Biol. 22, 3842-3851 (2002). (Pubitemid 34525225)
40. Heald, B. et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 139, 1927-1933 (2010).
41. Mina, S. et al. PTEN deletion is rare but often homogeneous in gastric cancer. J. Clin. Pathol. 65, 693-698 (2012).
42. Schepers, A. G. et al. Lineage tracing reveals Lgr5 stem cell activity in mouse intestinal adenomas. Science 337, 730-735 (2012).
43. Takaishi, S. et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27, 1006-1020 (2009).
44. da Cunha, C. B. et al. De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Lab. Invest. 90, 1604-1614 (2010).
45. Jang, B. I., Li, Y., Graham, D. Y. & Cen, P. The role of CD44 in the pathogenesis, diagnosis, and therapy of gastric cancer. Gut Liver 5, 397-405 (2011).
46. Mayer, B. et al. De-novo expression of CD44 and survival in gastric cancer. Lancet 342, 1019-1022 (1993). (Pubitemid 23314804)
47. Simon, E. et al. The spatial distribution of LGR5 cells correlates with gastric cancer progression. PLoS One 7, e35486 (2012).
48. Groszer, M. et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumour suppressor gene in vivo. Science 294, 2186-2189 (2001). (Pubitemid 33150679)
49. Zheng, H. et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455, 1129-1133 (2008).
50. Magee, J. A. et al. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukaemia suppression. Cell Stem Cell 11, 415-428 (2012).
51. Zhang, J. et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441, 518-522 (2006). (Pubitemid 44050154)
52. Yap, T. A. et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 29, 4688-4695 (2011).
53. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
54. Soriano, P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21, 70-71 (1999). (Pubitemid 29036285)